A Troubling Trend For Personalized Medicine Patents

Law360, New York (December 4, 2012, 12:45 PM EST) -- On Nov. 20, 2012, a three-judge panel of the Court of Appeals of the Federal Circuit, in PerkinElmer Inc., and NTD Laboratories Inc. v. Intema Ltd. (2011-1577), held that the claims in U.S. Patent 6,573,103 (the ‘103 patent”) are invalid as drawn to noneligible subject matter under 35 U.S.C. § 101.

The ‘103 patent claims are directed to prenatal noninvasive diagnostic methods for risk of fetal Down syndrome. Perkinelmer is a nonprecedential decision that follows the Ass’n for Molecular Pathology v. PTO, 689, F3.d 1303 (Fed....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.